Methods and compositions for inducing protective immunity

Patent metadata

Field	Value
Publication number	US-11839652-B2
Application number	US-201816630744-A
Country	US
Kind code	B2
Filing date	Jul 17, 2018
Priority date	Jul 17, 2017
Publication date	Dec 12, 2023
Grant date	Dec 12, 2023

Abstract

This application relates to compositions comprising one or more CpG oligodeoxynucleotides complexed to nanoparticles comprising a gemini surfactant and optionally a muco-adhesive polymer, which can be used for intrapulmonary delivery to induce immunity in feed animals, and the methods of making and uses thereof.

First claim

The invention claimed is:

1. A composition comprising one or more CpG oligodeoxynucleotide(s) (CpG-ODN) complexed with nanoparticles comprising a gemini surfactant and a mucoadhesive polymer formulated for intrapulmonary use, wherein the one or more CpG-ODN is a class B CpG ODN, and the muco-adhesive polymer is selected from polyvinylpyrrolidone (PVP) carboxy methylcellulose (CMC), optionally sodium CMC (CMCNa), and combinations thereof.

2. The composition of claim 1 , wherein the composition is a micro-droplet composition or nebulized composition.

3. The composition of claim 1 , wherein the composition further comprises a lipid.

4. The composition of claim 1 , wherein the CpG-ODN is CpG 2007.

5. The composition of claim 1 , wherein the gemini surfactant has one or more of a hydrocarbon tail that is 12 to 18 carbons in length, a spacer 3 to 7 carbons in length.

6. The composition of claim 1 , wherein the muco-adhesive polymer is comprised in, complexed with or in the nanoparticle.

7. The composition of claim 1 , wherein the composition further comprises PEG and a phospholipid.

8. The composition of claim 7 , wherein the PEG is selected from PEG 400, polyethylene glycol monomethyl ether (mPEG), and propylene glycol (PG) and combinations thereof; and the phospholipid is selected from phosphatidylcholine, preferably 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC); soybean phosphatidylcholine, egg phosphatidylcholine and/or hydrogenated phosphatidylcholine, and phosphotidylethanolamine and/or wherein the phospholipid is PEGylated.

9. The composition of claim 3 , wherein, the gemini surfactant is Gemini 12-3-12 and the composition comprises phosphatidylcholine (PC); or wherein the nanoparticles comprise Gemini 12-3-12, CMCNa, PEG, and DPPC; Gemini 12-3-12, CMCNa, PEG 400, and DPPC or Gemini 12-3-12, PVP MW 10,000, PEG 400 and DPPC.

10. The composition of claim 8 , wherein the amount of DPPC in a formulation is about 0.1% to 20% (m/v) of total volume of the final composition.

11. The composition of claim 1 , wherein one or more of the amount of gemini surfactant used in the formulation is about 0.01% to 5% (m/v) of the total volume of the final composition; wherein the composition further comprises an excipient selected from PG or PEG and the amount of excipient is about 1% to 20% (m/v) of the total volume of the final composition; and the muco-adhesive polymer is selected from PVP MW 40,000, PVP MW 10,000 and CMCNa and the amount of muco-adhesive polymer used in the formulation is about 0.1% to 20% (m/v) of the total volume of the final composition.

12. The composition of claim 1 , wherein the composition is formulated for a dosage comprising at least 25 μg up to about 500 μg of CpG-ODN, or at least 100 μg of CPG-ODN and/or comprises sufficient CpG-ODNs for about 500 to 5000 doses.

13. The composition of claim 1 , wherein the composition further comprises an antigen, and wherein the composition has an average polydispersity index (PD) of less than 0.5, and/or has an average zeta potential of at least 32MV or wherein the composition is formulated for needle free intrapulmonary delivery.

14. A method for stimulating immunity in a feed animal, comprising administering to the feed animal by intrapulmonary delivery an effective amount of micro-droplets of a composition comprising one or more CpG-ODNs, wherein the composition is the composition of claim 1 .

15. The method of claim 14 , wherein one or more of: the composition is administered by natural inspiration, the feed animal is exposed to the composition for at least about 10 min, at least about 15 min, at least about 20 min, at least about 25 min, at least about 30 min, or at least about 35 min; and the administration is repeated.

16. The method of claim 14 , wherein the feed animal is a turkey, layer hen or a broiler chicken.

17. The method of claim 14 , wherein the feed animal is administered about 1 mg to about 4 mg of CpG-ODN/0.036 m 3 of chamber, or wherein the feed animal is administered about 25 μg to about 500 μg of CpG-ODN.

18. The method of claim 14 wherein the feed animal is administered the composition in chamber where the average temperature is about 22° C. to about 24° C.

19. The composition of claim 3 , wherein the lipid is DPPC, the gemini surfactant is gemini 12-3-12, the CpG-ODN, comprises a sequence of SEQ ID NO: 1, and the composition further comprises an excipient, said excipient being propylene glycol.

20. The composition of claim 1 , wherein the ratio of gemini surfactant to CpG-ODN is between 1.5:1 to 3:1.

Assignees

• Univ Saskatchewan

Inventors

• Gomis Susantha
• Popowich Shelly
• Goonewardene Kalhari Venukala Bandara
• Tikoo Suresh
• Foldvari Marianna

Classifications

• A61K39/39 Primary

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• A23K20/153

  Nucleic acids; Hydrolysis products or derivatives thereof · CPC title

• A23K50/75

  for poultry · CPC title

• C12N15/117

  Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs · CPC title

• A61K9/0078

  for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions · CPC title